NCT04778800Unknown不适用
A Dose Exploration Study of Almonertinib for Epidermal Growth Factor Receptor(EGFR)-Mutant Non-small-cell Lung Cancer(NSCLC) Patients With Newly Diagnosed or Recurrent Brain/Leptomeningeal Metastasis (ARTISTRY)
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- iPFS
研究概览
简要总结
Almonertinib is a three-generation epidermal growth factor receptor tyrosine kinase inhibitor(EGFR-TKI), which has shown competitive potential in the second-line treatment against first-generation TKIs. This study aims to explore the efficacy and safety of different doses of almonertinib in the first-line and second-line treatment of brain metastases/meningeal metastases in NSCLC patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female,age at least 18 years ;
- •Histologically confirmed patients with NSCLC brain metastases (including patients who have relapsed after previous treatment or newly diagnosed);
- •There must be at least one measurable brain lesion that has not been locally treated at the time of enrollment;
- •Patients who have not received other systemic treatment after the diagnosis of NSCLC brain metastasis, or patients who have received neoadjuvant therapy, adjuvant therapy, concurrent radiotherapy and chemotherapy, and local radiotherapy for more than 6 months;
- •Tumor tissue samples or blood are confirmed to be EGFR sensitive mutations (including exon 19 deletion or L858R) by ARMS;
- •The Eastern Cooperative Oncology Group (ECOG) physical status score is 0-2 and has not deteriorated in the previous 2 weeks, with a minimum expected survival of 12 weeks;
- •The patient is not required to have measurable systemic lesions; if there is, the lesions are required to be in at least one dimension (the largest diameter recorded by non-nodular lesions and the short axis of nodular lesions) ≥10mm by conventional techniques (CT, MRI) Can be accurately measured under the circumstances;
- •The subject himself voluntarily participated and signed an informed consent form.
- •Male or female,age at least 18 years ;
- •Histologically confirmed NSCLC patients (including patients who have relapsed after previous treatment or newly diagnosed);
- •Tumor cells found in cerebrospinal fluid or MRI showed clear meningeal enhancement and patients with dizziness/headache were included as selection criteria;
- •Patients who have not received other systemic treatment after being diagnosed with stage IV NSCLC, or patients who have received neoadjuvant therapy, adjuvant therapy, and concurrent radiotherapy and chemotherapy for more than 6 months;
- •The tumor tissue samples or blood are confirmed to be EGFR sensitive mutations (including exon 19 deletion or L858R) by ARMS;
- •The Eastern Cooperative Oncology Group (ECOG) physical status score is 0-2 and has not deteriorated in the previous 2 weeks, with a minimum expected survival of 12 weeks;
- •The patient is not required to have measurable systemic lesions; if there is, the lesions are required to be in at least one dimension (the largest diameter recorded by non-nodular lesions and the short axis of nodular lesions) ≥10mm by conventional techniques (CT, MRI) Can be accurately measured under the circumstances; The subjects themselves participated voluntarily and signed a written informed consent form.
- •Male or female,age at least 18 years ;
- •Histologically confirmed patients with stage IV NSCLC (including relapsed or newly diagnosed stage IV patients after previous treatment);
- •Patients with brain progression or brain lesions that have not resolved after the first/second generation EGFR-TKI treatment;
- •The patient must have at least one measurable brain lesion that has not been locally treated at the time of enrollment;
- •The tumor tissue samples or blood are confirmed to be EGFR sensitive mutations (including exon 19 deletion or L858R) by ARMS;
- •The Eastern Cooperative Oncology Group (ECOG) physical status score is 0-2 and has not deteriorated in the previous 2 weeks, with a minimum expected survival of 12 weeks;
- •The patient is not required to have measurable systemic lesions; if there is, the lesions are required to be in at least one dimension (the largest diameter recorded by non-nodular lesions and the short axis of nodular lesions) ≥10mm by conventional techniques (CT, MRI) Can be accurately measured under the circumstances;
- •The subject himself voluntarily participated and signed an informed consent form.
排除标准
- •the researchers believe that the risks faced by patients after entering the group are greater than those who benefit from them.
- •patients involved in any other clinical study.
- •patients with other malignant tumors.
- •A history of allergic reactions caused by compounds similar to almonertinib or its chemical composition.
- •pregnant or lactating women.
- •researchers should not participate in the study if they believe that patients cannot comply with the research procedures and requirements.
研究组 & 干预措施
almonertinib 110mg PO once daily
Experimental
干预措施: almonertinib (Drug)
almonertinib 160mg PO once daily
Experimental
干预措施: LM-first line treatment (Drug)
almonertinib 220mg PO once daily
Experimental
干预措施: LM-second line treatment (Drug)
结局指标
主要结局
iPFS
时间窗: Up to approximately 3 years after the last patient is randomized
Intracranial progression-free survival (iPFS)
次要结局
- PFS(Up to approximately 3 years after the last patient is randomized)
- DCR(Up to approximately 3 years after the last patient is randomized)
- OS(Up to approximately 3 years after the last patient is randomized)
研究者
wanghj
associate chief physician
Henan Cancer Hospital
研究点 (1)
Loading locations...
相似试验
Unknown
2 期
A Phase II Trial of Upfront Radiotherapy Plus Almonertinib for Epidermal Growth Factor Receptor(EGFR)-Mutant Non-small-cell Lung Cancer(NSCLC) Patients With Brain MetastasesEGFR Positive Non-small Cell Lung CancerBrain MetastasesNCT04643847First People's Hospital of Hangzhou47
已完成
1 期
EGFR Inhibition Using Weekly Erlotinib for Recurrent Malignant GliomasBrain CancerNCT01257594Andrew B Lassman, MD22
已完成
2 期
Combination of Osimertinib and Aspirin to Treat 1st Generation EGFR-TKI Resistance in NSCLCNon-Small Cell Lung Cancer Stage IIIBNon-small Cell Lung Cancer Stage IVEGFR T790MNCT03543683Daping Hospital and the Research Institute of Surgery of the Third Military Medical University115
Unknown
不适用
Combination of Osimertinib and Aspirin to Treat Osimertinib Resistance Non-small Cell Lung Cancer ( NSCLC)Non-Small Cell Lung Cancer Stage IIIBNon-small Cell Lung Cancer Stage IVEGFR T790MNCT03532698Daping Hospital and the Research Institute of Surgery of the Third Military Medical University100
已完成
2 期
Combination of Osimertinib and Aspirin to Treat EGFR Mutation NSCLC PatientsLung Cancer Non-small Cell Stage IVNCT04184921Daping Hospital and the Research Institute of Surgery of the Third Military Medical University216